cdk4/6 inhibitors: closing the express lane in breast cancer
Published 1 month ago • 30 plays • Length 2:25Download video MP4
Download video MP3
Similar videos
-
2:11
the use of frontline cdk4/6 inhibitors endocrine therapy in metastatic breast cancer
-
19:09
breast cancer breakthroughs episode 9: new frontiers in early er-positive breast cancer
-
29:09
interactive case: choosing and using cdk4/6 inhibitors in breast cancer - first-line therapy
-
2:06
unmet needs and cdk4/6 inhibitors in hr /her2- early breast cancer
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
16:39
breast cancer breakthroughs episode 10: top takeaways from asco 2024
-
7:40
cdk4/6 inhibitors in the first-line treatment setting
-
5:07
what is the role of cdk4/6 inhibitors in early breast cancer?
-
4:35
hr breast cancer: differences between cdk4/6 inhibitors
-
21:11
current clinical data for cdk 4/6 inhibitors in breast cancer
-
8:55
cdk4/6 inhibitors in hr metastatic breast cancer
-
5:57
cdk4/6 inhibitors in the second-line treatment setting
-
17:54
expert perspectives: cdk 4/6 inhibitors for er breast cancer: current data and clinical use
-
8:28
cdk4/6 inhibition in breast cancer
-
9:18
clinical experience: cdk4/6 inhibitors in breast cancer
-
4:54
monarch 3 study: cdk4/6 inhibitors in the treatment of metastatic breast cancer
-
4:52
future directions: cdk4/6 inhibitors in breast cancer